A Public Health Strategy for the Opioid Crisis

Brendan Saloner, PhD\(^1\), Emma E. McGinty, PhD, MS\(^1\), Leo Beletsky, JD, MPH\(^2,3\), Ricky Bluthenthal, PhD\(^4\), Chris Beyrer, MD, MPH\(^5\), Michael Botticelli, MEd\(^1,5,6\), and Susan G. Sherman, PhD\(^7\)

Abstract

Drug overdose is now the leading cause of injury death in the United States. Most overdose fatalities involve opioids, which include prescription medication, heroin, and illicit fentanyl. Current data reveal that the overdose crisis affects all demographic groups and that overdose rates are now rising most rapidly among African Americans. We provide a public health perspective that can be used to mobilize a comprehensive local, state, and national response to the opioid crisis. We argue that framing the crisis from a public health perspective requires considering the interaction of multiple determinants, including structural factors (eg, poverty and racism), the inadequate management of pain, and poor access to addiction treatment and harm-reduction services (eg, syringe services). We propose a novel ecological framework for harmful opioid use that provides multiple recommendations to improve public health and clinical practice, including improved data collection to guide resource allocation, steps to increase safer prescribing, stigma-reduction campaigns, increased spending on harm reduction and treatment, criminal justice policy reform, and regulatory changes related to controlled substances. Focusing on these opportunities provides the greatest chance of making a measured and sustained impact on overdose and related harms.

Keywords

addiction, health disparities, health policy, injury, pain management, stigma

In 2016, 64,000 people died from drug overdose in the United States.\(^1\) Overdose is now the leading cause of injury death in the United States, contributing to an unprecedented decline in life expectancy among non-Hispanic white people without a college degree.\(^2\) The current drug overdose crisis is substantially driven by opioids, which accounted for 42,000 deaths in 2016, a 5-fold increase since 1999.\(^1\) Much of the current response to this crisis, which is aimed at reducing the wide-ranging health consequences of the opioid epidemic, lacks comprehensive vision and strategy. Public health approaches that focus on reducing overdose risk among the most vulnerable populations show great promise, but implementing these approaches requires policies rooted in a broad conceptualization of the drivers of the epidemic.

Understanding the Opioid Epidemic

Epidemiological and clinical data provide context for understanding the range of adverse outcomes directly related to fatal opioid overdose, opioid use and misuse, and opioid use disorder; the medical and social consequences that are driven by opioid misuse; and programs and policies that may either contribute to or mitigate negative outcomes (Table 1).

---

1 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2 School of Law and the Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA
3 School of Medicine, University of California, San Diego, La Jolla, CA, USA
4 Department of Preventive Medicine and the Institute for Prevention Research at the Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
5 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
6 Grayken Center for Addiction at Boston Medical Center, Boston, MA, USA
7 Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Corresponding Author:
Brendan Saloner, PhD, Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, 624 N Broadway, Room 344, Baltimore, MD 21205, USA.
Email: bsaloner@jhu.edu
Table 1. Major indicators tracking the opioid overdose epidemic: current state of knowledge and key limitations

<table>
<thead>
<tr>
<th>Indicator</th>
<th>What We Know</th>
<th>Key Limitations of Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatal opioid overdose rates and types of opioids associated with overdose</td>
<td>• Opioid overdose rates have increased 5-fold since the late 1990s.¹</td>
<td>• Known miscoding/undercoding by coroners and medical examiners</td>
</tr>
<tr>
<td></td>
<td>• Most overdoses are associated with opioids, and heroin and synthetics are the fastest rising categories.²</td>
<td></td>
</tr>
<tr>
<td>Nonfatal opioid overdoses</td>
<td>• Nonfatal opioid overdoses are rising across the United States.³</td>
<td>• Nonfatal overdoses not captured in national surveys of people who use drugs</td>
</tr>
<tr>
<td></td>
<td>• Heroin supply reductions can reduce nonfatal opioid overdoses.⁴</td>
<td>• Limited longitudinal data on people who use drugs</td>
</tr>
<tr>
<td>Use of prescribed opioid pain relievers</td>
<td>• Prescriptions for opioid pain relievers rapidly increased until 2012 and have begun declining.⁵</td>
<td>• Difficult to know patients’ intentions and experiences</td>
</tr>
<tr>
<td></td>
<td>• US patients are much more likely to be prescribed opioids than patients in other countries.⁶</td>
<td>• Difficult to measure diversion from patient</td>
</tr>
<tr>
<td>Nonmedical use of pain relievers, use of heroin, and opioid use disorder</td>
<td>• The number of people who misuse prescription opioids has declined since the mid-2000s,⁷ whereas the number of people who use heroin has increased.⁸</td>
<td>• Derived from household surveys with known high underresponse rates</td>
</tr>
<tr>
<td>National drug laboratory data</td>
<td>• Heroin has become more widely available and more likely to be laced with fentanyl.⁹</td>
<td>• Does not capture incarcerated and homeless populations</td>
</tr>
<tr>
<td>Harm reduction</td>
<td>• Access to naloxone and syringe services has grown in recent years.¹⁰</td>
<td>• Not necessarily representative of drugs sold in many markets</td>
</tr>
<tr>
<td></td>
<td>• Safe consumption does not legally exist in the United States.¹¹</td>
<td>• Difficult to quantify access to harm-reduction services in at-risk populations</td>
</tr>
<tr>
<td>Criminal justice involvement</td>
<td>• Many people with opioid use disorder enter the criminal justice system.¹²</td>
<td>• Limited data on differences in policing and sentencing tactics in various areas</td>
</tr>
<tr>
<td></td>
<td>• Leaving jail/prison greatly increases the risk for overdose.¹³</td>
<td>• Few surveys of arrestees and justice-involved populations</td>
</tr>
<tr>
<td>Incidence of HIV and hepatitis C virus (HCV)</td>
<td>• A national HCV outbreak has been related to injection drug use.¹⁴</td>
<td>• Limited surveillance and contact tracing for acute HCV infection to interrupt outbreaks</td>
</tr>
<tr>
<td></td>
<td>• HIV incidence is increasing among younger people.¹⁵</td>
<td></td>
</tr>
<tr>
<td>Hospitalizations and data on nonfatal overdoses</td>
<td>• Hospitalizations have increased across various opioid-related diagnoses.¹⁶</td>
<td>• Many nonfatal overdoses are not captured in hospital records and may be undercoded</td>
</tr>
<tr>
<td>Access to drug treatment programs</td>
<td>• Only one-fifth of people with opioid use disorder receive any treatment.¹⁷</td>
<td>• No national database fully captures trends in methadone and buprenorphine treatment</td>
</tr>
<tr>
<td></td>
<td>• Most people with opioid use disorder continue to be treated without opioid agonists.¹⁸</td>
<td>• Undercoverage of some treatment programs by insurers</td>
</tr>
</tbody>
</table>

Opioid Overdose Deaths

Most fatal opioid overdoses in the early 2000s were exclusively linked to prescription medication, yet most opioid overdoses today involve heroin and illicit fentanyl. Nationally, people who died of opioid overdose in recent years were disproportionately white, male, middle-aged adults.¹ Unlike the last major national surge of heroin use in the 1970s, which mainly affected urban minority populations, since the 2000s, opioid overdose rates have been elevated in urban, suburban, and rural communities.¹⁷ Geographically, the greatest burden of overdoses is in Appalachia, the Southwest, and New England.¹ These realities, combined with rising political attention to rural and low-income white people in the United States, may explain increased interest in addressing opioid overdose in these hard-hit regions.¹⁸ Trends among other affected populations are also concerning. For example, drug overdose mortality among Native Americans has been highly elevated since the inception of the drug overdose crisis in the early 2000s, and the incidence of overdose mortality among African Americans is now rising faster than among other racial/ethnic groups.¹⁸

Opioid Use and Misuse, and Opioid Use Disorder

Consistent with the mortality shift away from prescription opioids and toward illicit opioids, national data indicate that opioid prescription volume leveled during the past decade, although it is higher than in many peer countries.⁵ Simultaneously, the potency and lethality of street drugs increased, because heroin is frequently adulterated with fentanyl.¹⁹ Fentanyl is increasingly entering the cocaine and methamphetamine supply.⁹ The 2016 National Survey of Drug Use and Health estimated that at any point in the year, 92 million people in the United States used opioid pain relievers,²⁰ 11.5 million misused opioid pain relievers, 0.9 million used heroin, and 2.1 million had symptoms of an opioid use disorder (ie, opioid use caused impairment and/or dependence).²¹ National Survey of Drug Use and Health data indicate that misuse of
prescription opioids has declined since the mid-2000s.\textsuperscript{22} These data mirror trends in medical claims and administrative databases, which track quantities of opioids legally distributed in various areas\textsuperscript{7} and provide insight into the dosage and quantity of prescription opioids used by patients.\textsuperscript{23} Patients who use high-dosage opioids are broadly distributed across the medical system, rarely concentrating in practices that might be considered “pill mills” (ie, clinics with aberrant prescribing),\textsuperscript{24} suggesting that efforts to change prescribing likely need to be broadly targeted. National Survey of Drug Use and Health data also indicate that the number of heroin users has increased, and the demographic characteristics of people who use heroin have also changed; most new users are non-Hispanic white and, increasingly, female.\textsuperscript{25} High-risk opioid use and negative outcomes disproportionately affect urban communities\textsuperscript{26} and vulnerable groups, including the criminal justice–involved population,\textsuperscript{11} sex workers,\textsuperscript{27} and gender minority populations.\textsuperscript{28}

\textbf{Other Adverse Outcomes}

Medical claims data track nonfatal opioid overdose and medical comorbidities.\textsuperscript{14} Opioid-associated infections (eg, hepatitis C virus\textsuperscript{12} and HIV among younger groups\textsuperscript{13}) have risen in recent years. The opioid crisis has increased the prevalence of neonatal abstinence syndrome, a transient withdrawal syndrome after birth following an opioid-exposed pregnancy that lasts several days to several weeks.\textsuperscript{29} Neonatal abstinence syndrome can occur when mothers receive methadone or buprenorphine and, in these cases, can be managed without negative long-term effects on infant health.\textsuperscript{30} In cases in which this syndrome is associated with an unstable home environment, a child’s subsequent healthy development is at risk. Areas hit hardest by the opioid epidemic have had higher rates of foster care involvement than areas where the opioid epidemic has been less severe.\textsuperscript{31} Opioid use and economic stress are likely related, with some evidence suggesting that opioid use is associated with economic hardship\textsuperscript{32} and absence from the labor market.\textsuperscript{33}

\textbf{Programs and Policies}

Access to treatment and harm-reduction programs is growing but remains limited. In 2004-2013, only one-fifth of people with opioid use disorder received treatment.\textsuperscript{15} Admissions-level data on drug treatment programs show that in 2005-2015, only one-quarter of patients received opioid agonist treatment (eg, methadone or buprenorphine), the treatment option best supported by clinical evidence.\textsuperscript{16} About half of all people who inject drugs used syringe service programs in 2015, an increase from one-third of all people who inject drugs in 2005.\textsuperscript{34} The amount of naloxone dispensed by retail pharmacies increased 12-fold from late 2013 to mid-2015, and the number of naloxone kits distributed to laypeople increased 3-fold from 2010 to 2014.\textsuperscript{35} Naloxone distribution programs can help reduce opioid overdose deaths by putting life-saving medication in the hands of people who are close to overdose victims.\textsuperscript{36}

\textbf{Limitations of Current Data}

Lack of standardization in toxicology and coding practices among medical examiners and coroners can lead to misclassification of cause of death, poor identification of types of opioids involved in overdoses, and undercounting of intentional poisonings.\textsuperscript{37-41} Additionally, focusing on mortality does not adequately disentangle fatality risk per user (or per use) over time and specific drugs involved in overdoses—research questions that could be informed by nonfatal overdose surveillance data or drug seizure data.\textsuperscript{42}

Although the National Survey of Drug Use and Health does sample people with a history of criminal justice involvement, it does not include data on people who are in jails or prisons or homeless people. The now-defunct Arrestee Drug Abuse Monitoring program provided useful surveillance data on drug use among arrestees.\textsuperscript{43} Similarly, data on illicit drug markets, including price and purity of street drugs and the intersection between opioids and other illicit drugs, are limited. Finally, although robust epidemiological studies have been performed for small geographic areas,\textsuperscript{44} nationally representative longitudinal studies of people who use opioids are lacking, making it difficult to examine initiation of use and transition across various misused substances (eg, prescribed opioids, heroin).

Evaluating policy change is also problematic. Multiple legislative and programmatic interventions are often pursued simultaneously,\textsuperscript{45} thereby complicating efforts to discern the effects of a particular element. For example, mixed evidence on the effectiveness of prescription drug monitoring programs\textsuperscript{46-57} may stem from challenges in isolating their effects when states simultaneously implement laws on expanded naloxone access, pain clinic regulation, and opioid prescribing caps.\textsuperscript{54} Finally, data are limited on how accessible various types of programs and services are to people who use opioids, making it difficult to quantify the effectiveness of these programs in improving health and safety.

\textbf{Framing the Opioid Epidemic as a Public Health Issue}

The national dialogue around opioids has been dominated by several approaches that on their own are inadequate or harmful. “War on drugs” approaches that would increase arrests and incarceration to deter drug use and distribution have had long-term scarring effects on many communities, primarily those of color,\textsuperscript{55,56} without measurably reducing access to street drugs.\textsuperscript{57,58} Likewise, defining drug use as an individual’s moral failing that can be remedied through willpower alone is inconsistent with biological triggers that create susceptibility to addiction.\textsuperscript{54} The moral failing approach also fails to recognize the role of trauma and adverse childhood experiences in addiction. Most importantly, the willpower
approach lacks evidence for efficacy. Likewise, a single-minded focus on abstinence led to opposition from several self-help advocates against highly effective treatments such as methadone, buprenorphine, and harm reduction. Moving beyond moralized and punitive approaches to addiction could help reduce stigma and increase acceptance of treatment, not only for people who use opioids but also for the safety and wellbeing of society at large.

Drawing on ecological models of health behavior (eg, McLeroy’s model, which posits that health outcomes emerge from the interaction of individual, institutional, community, and policy factors), we developed a novel public health approach that draws attention to multiple determinants of drug use and emphasizes the role of upstream factors that drive addiction, overdose, and associated social outcomes. At the center is the interaction between individual drug use behaviors and drug use context; a particular opioid use behavior (eg, injection) is more likely to result in negative outcomes when it occurs in an unsafe environment than, for example, when it occurs in a supervised consumption context. Both context and behaviors are influenced by upstream factors. Structural factors reflect social and economic conditions that drive social disadvantage and lack of opportunity in many communities. Structural factors influence, and are influenced by, the drug supply environment and by health, criminal justice, economic, and social policy. These policy factors also have a downstream influence on services and systems that interact with people who use drugs, particularly opioids. Individual health and social outcomes are driven by the nexus between drug use behaviors and the drug use context. We posit that health and social outcomes flow back to structural factors, because living in communities with a high prevalence of overdose has an adverse effect on the social and economic environment.

These complex factors are inadequately reflected in current data. Our public health approach posits that harmful drug use is closely intertwined with social structures that create stigma and isolation, the labor market, and the functioning of the public safety net. Once the contributors to overdose are reconceptualized from a public health lens, it becomes clear that reducing morbidity and mortality associated with the use of opioids can be fully achieved only by simultaneously addressing the forces that drive opioid use, the context of drug use, and the factors making such use increasingly lethal.

Opportunities for Public Health Impact

Several approaches could decrease opioid overdoses and other harms associated with opioid drug use if implemented to scale. These elements could form the basis for a national response strategy focused on opioid overdose risk (Table 2). These approaches are optimally pursued through partnership among federal, state, and local government.

Improving Data Collection

Data collection can be improved by building overdose tracking into existing sentinel surveillance systems focused on vulnerable populations (eg, men who have sex with men and people who inject drugs). Implementing new surveillance systems requires overcoming legal and data exchange barriers. Ideally, practitioners could track local risk factors in real time and identify the resources (eg, naloxone distribution) that can mitigate risks. One area of data collection that has recently seen progress is developing dashboards, such as Rhode Island’s PreventOverdose, RI, which reports timely statewide data on key indicators, including overdose incidence and admissions to specialty treatment programs. States can invest in improving drug overdose fatality surveillance, which has improved the accuracy of data collected in states such as Kentucky. Creating data warehouses that link individual-level records across multiple public service systems (eg, Massachusetts through its Chapter 55 legislation) is another promising strategy.

Safer Prescribing

Improving opioid prescribing practices has the potential to prevent addiction. Efforts to improve prescribing need to be aligned with broader efforts to deliver patient-centered pain treatment deploying a range of treatment modalities. Opioids have important clinical benefits in some contexts, including management of pain from cancer, sickle-cell disease, and acute injuries, whereas risks of long-term opioid therapy for chronic noncancer pain resulting from conditions such as lower back pain, headache, and osteoarthritis often outweigh the benefits. The 2016 Centers for Disease Control and Prevention guidelines for prescribing opioids for chronic pain offer helpful criteria for how clinicians should consider various pain treatment options, including opioid and nonopioid pharmacotherapies (eg, ibuprofen) and nonpharmacologic pain treatments (eg, physical therapy) that have been shown to be safer and more effective than opioids in some contexts.

Several measures can be taken to improve opioid prescribing. The first is educating clinicians and patients. It is important to manage patient expectations (eg, that some pain is expected after a surgery) and to talk with patients about goals other than pain relief, such as improving functional status. Insurers often inadequately cover nonpharmacologic pain treatments such as physical therapy, suggesting a need for changes in pain treatment reimbursement policies. A second measure is to better integrate addiction medicine with pain management, because many patients with opioid use disorder also have chronic pain. The worst outcome is for physicians managing pain to refuse to treat patients who demonstrate signs of opioid dependence. Instead, physicians have a duty to either treat dependence (eg, by using buprenorphine) or develop a clear linkage to specialty care. Achieving such integration will require various financing...
Figure. A conceptual framework for the opioid overdose epidemic.
(eg, mechanisms for pain specialists to be reimbursed for coordinating addiction care) and delivery (eg, sharing medical records across pain management and addiction treatment providers) strategies.

<table>
<thead>
<tr>
<th>Key Priority</th>
<th>Strategy</th>
<th>Responsible Group</th>
</tr>
</thead>
</table>
| Improved data collection | • Build overdose tracking into existing sentinel surveillance systems.  
                            • Create data dashboards that link information across service systems. | • Legislatures should pass bills to support data surveillance and linkage.          |
| Safer prescribing      | • Increase physician and patient awareness of opioid benefits and risks.  
                            • Integrate addiction treatment with pain management. | • Epidemiologists and other researchers should work with policy makers to analyze new databases. |
| Stigma reduction       | • Use destigmatizing language and imagery in news media, government communication, and medical practice.  
                            • Implement stigma-reduction campaigns that use messages intended to influence public opinion, tested by using experimental methods. | • Professional associations representing physicians should partner with patient advocacy organizations and payers to increase uptake of comprehensive pain management protocols. |
| Harm reduction         | • Offer universal access to syringe services programs, fentanyl test kits, and naloxone.  
                            • Provide access to safe consumption facilities (ie, places where people can consume previously purchased drugs under medical supervision). | • News organizations, government agencies, and medical organizations should adopt new policies and practices to ensure that language and imagery are not stigmatizing. |
| Treatment expansion    | • Offer universal access to treatment on demand with opioid agonists.  
                            • Deregulate treatment to make methadone easier to access and buprenorphine easier to prescribe. | • Government and foundations should sponsor scientifically tested campaigns focused on reducing negative attitudes and increasing treatment and harm-reduction service uptake. |
| Criminal justice reform| • Expand prearrest diversion programs (programs that provide people with treatment alternatives to jail).  
                            • Make changes in policing practices to reduce adversarial encounters with people who use drugs.  
                            • Provide universal medication-assisted treatment in jails and prisons. | • Congress should appropriate new funds and change laws around safe consumption facilities. |
| Regulatory change      | • Align the regulations for controlled substances with best public health evidence. | • US Department of Justice should change its prohibition of safe consumption facilities. |

**Stigma Reduction**

Many people in the United States believe that people with opioid use disorder are to blame for their addiction and do not want to work closely with them or have them marry into their families. Stigma toward people who use opioids is correlated with low support for allocating substance use treatment resources and high preference for punitive policies. Furthermore, stigma can impede help seeking by people with drug problems because they may fear negative social, legal, and employment repercussions if they disclose their drug use. Personal stories describing the experiences of people who use opioids can reduce stigma, as can messages emphasizing the effectiveness of treatment and depicting examples of successful treatment and recovery.

Language used when discussing addiction also matters. Person-centered language (eg, “person with a substance use disorder” as opposed to “addict”) is destigmatizing. Several promising efforts are underway to destigmatize opioid use disorder through such language changes.

Reducing stigmatizing attitudes among law enforcement, clinicians, emergency medical responders, and others who work closely with people who use opioids should be a priority of public health policy makers.

**Harm Reduction**

Many fatal and nonfatal overdoses can be prevented by changing the circumstances surrounding drug use. Changing
circumstances includes improving the safety of the drugs themselves and the environments in which drugs are used. Expanded access to naloxone among people who use drugs, nearby peers, family, and friends is needed. National and local data indicate that many overdose reversals are enacted by fellow drug users. Although overdose education programs, naloxone programs, and syringe services programs can deploy peer employees to provide life-saving services to those at risk for overdose death, formal overdose education and naloxone programs that use peers have not been expanded upon in the United States.

From the early days of the HIV epidemic, syringe services programs were shown to be a cost-effective, low-threshold strategy to reduce blood-borne infections. They also can reduce fatal overdoses through education and naloxone distribution and substantially increase uptake of drug treatment. Safe consumption spaces (ie, places where individuals can consume previously purchased drugs under medical supervision) and drug-checking services (which help people to identify adulterants in drugs they have obtained) are underused in the United States but are an important harm-reduction approach throughout Europe. For example, most street drug users in the United States seek to avoid fentanyl but lack the knowledge of how to do so. Bucking opposition from the US Department of Justice, jurisdictions such as San Francisco, Seattle, and Philadelphia adopted comprehensive plans for safe consumption spaces, providing a model for others to follow.

**Treatment Expansion**

Improving treatment uptake requires bringing effective treatments to people when they need them most, without barriers such as waitlists, travel distance, and high out-of-pocket cost. Promising innovations in the treatment-on-demand approach, such as buprenorphine induction in emergency departments and comprehensive treatments in jails, have been introduced. These approaches can be optimally combined with continued treatment in the community after release from jails and hospitals. Communities have overcome obstacles such as waitlists by linking specialty treatment to office-based prescribers. For example, the “hub-and-spoke” model in Vermont creates partnerships between office-based prescribers and specialty care to create better integration of services. Promising investments have been made in developing the treatment workforce, such as providing additional funding to states through grants authorized by the 21st Century Cures Act.

Sustained progress, however, requires bolder action. First, Congress needs to expand its commitment to financing treatment through Medicaid and other federally funded programs. Medicaid expansion through the Affordable Care Act has been an important lever for increasing resources for substance use treatment, but it has not been adopted in many states and has been continually threatened by repeal efforts. Beyond expanding insurance coverage, Medicaid and private insurers need to support long-term recovery options, eliminate barriers to effective medications, and cover a wider array of treatments (eg, peer services, vocational support).

Second, opioid agonist treatments must be easier to access and less expensive than illicit opioids. Buprenorphine is tightly regulated. Scope-of-practice laws prevent nurse practitioners from prescribing buprenorphine in many states despite recent federal policy change. Beyond the scope of practice, eliminating the additional regulations placed on buprenorphine prescribing altogether is likely to be beneficial. When France ended buprenorphine restrictions in the 1990s, access to buprenorphine increased and overdoses decreased. Likewise, methadone is available only in opioid treatment programs, but several peer countries have made it available at pharmacies. Several states, including West Virginia, are beginning to cover methadone maintenance; however, more than a dozen states do not cover methadone maintenance under Medicaid. Finally, ending spending on ineffective approaches, such as treatment that is administered under the coercion of civil commitment laws, can improve outcomes. Licensing bodies should require providers to offer access to (or linkages with) opioid agonist treatment and withhold licensure from providers that do not meet this standard of care.

**Criminal Justice Reform**

Although the mantra that “we cannot arrest our way out of this problem” has gained adherents in recent years, the US Department of Justice is interested in increasing criminal prosecution of people who use drugs. This tough-on-crime approach has a high likelihood of backfiring: overzealous law enforcement can lead fewer people to come forward when their companions are overdosing, thereby increasing health risks. Likewise, reducing the minimum amount of fentanyl required by law to trigger federal mandatory minimum sentencing could encourage the sale and distribution of even more concentrated fentanyl doses, which would increase the drug’s lethality. However, police, courts, and correctional settings can improve access to treatment and harm reduction. The growing use of naloxone by law enforcement and the implementation of Good Samaritan laws that protect people who summon law enforcement in the event of an overdose are promising models. Public health and public safety goals are more closely aligned than has been traditionally recognized, although disparate metrics, intervention modalities, professional cultures, and resource competition have so far prevented collaboration.

Recalibrating criminal justice approaches requires examining policies governing drug use, dealing, and prior convictions. Policy change is necessary but is insufficient to transform criminal justice practice; as such, aligning policing with public health goals also requires transforming the tools and incentives used in street-level policing. Broader criminal justice reform efforts, such as improving police accountability, diversity, and training, are also critical to reorienting police practice. Several jurisdictions including Seattle, which
adopted the Law Enforcement Assisted Diversion program, have had success with programs offering treatment and harm-reduction services as an alternative to arrests.\textsuperscript{105} Broader diffusion of these programs should be a priority.

\textbf{Regulatory Change}

Deregulation of medication-assisted treatment and targeted decriminalization approaches are incremental steps toward a reevaluation of the federal controlled substances regulatory system. Under the federal Controlled Substances Act, the US Drug Enforcement Agency has broad purview over health care and pharmacy practices as they relate to controlled substances. The US Drug Enforcement Agency has been driven by criminal justice metrics that bear little relation to public health and lack the scientific expertise to appropriately calibrate patient care. Better public health outcomes could result if the regulatory system were reevaluated based on the likely balance of risks and benefits to public health. This process should be holistic in its focus on overall health and consider opioid regulations alongside other controlled substances. For example, marijuana is a promising alternative pain-relief medication, although marijuana also carries its own health risks.\textsuperscript{107}

\textbf{Conclusion}

The United States is in the midst of an opioid crisis that will not abate without sustained public health interventions. Many policy makers are seeking solutions in the wrong places, and we believe that criminal penalties and a commitment to abstinence-only methods will cause more people to needlessly die of overdoses and will fail to keep the public safe. As in the early days of the AIDS epidemic, political will needs to be built to effect change, and a vision is needed to create policies that will actually work to reduce overdose. Public health has an important role in helping to understand why people use drugs, offering less stigmatizing strategies to assist people who use opioids, and disseminating innovative programs that help these populations to safely use drugs, receive treatment, and enter long-term recovery. Ultimately, overdose deaths are preventable, lives can be saved, and people can recover, regain stability, and have productive futures.

\textbf{Declaration of Conflicting Interests}

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

\textbf{Funding}

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Brendan Saloner and Susan G. Sherman gratefully acknowledge funding support from the Bloomberg American Health Initiative. Funding support from the National Institute on Drug Abuse is acknowledged by Brendan Saloner (K01 DA042139), Leo Beletsky (R01DA039073 [multiple principal investigators: Beletsky/Strathdee]) and R37DA019829 [principal investigator: Strathdee]), and Ricky Bluthenthal (R01DA038965 [multiple principal investigators: Bluthenthal/Kral]). This article was produced with the support of the Bloomberg American Health Initiative, which was funded by a grant from the Bloomberg Philanthropies.

\textbf{References}


44. Carlson RG, Nahhas RW, Martins SS, Danuilaityte R. Predicators of transition to heroin use among initially non-opioid...
76. Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: associations with public


